Selecta Biosciences, Inc. (NASDAQ:SELB) clinical-stage biopharmaceutical firm, is reporting third quarter earnings results on Thursday 5th November 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 0.10 per share from $ 23.93 million in revenue.
For the full year, analysts predict revenues of $ 29.37 million, while looking forward to loss of $ 0.42 per share.
Stock Performance
Shares of Selecta Biosciences, Inc. traded up $ 0.16 or 5.10 percent on Wednesday, reaching $ 3.30 with volume of 2.80 million shares. Selecta Biosciences, Inc. has traded high as $ 3.41 and has cracked $ 3.17 on the downward trend
The closing price of $ 3.30, representing a 143.41 % increase from the 52 week low of $ 1.29 and a 34.99 % decrease over the 52 week high of $ 4.83.
The company has a market capital of $ 353.57 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 5th October 2020, maintained by HC Wainwright at Buy rating, with $ 6.00 target price.
- On 1st October 2020, downgraded by William Blair to Market Perform from Outperform rating.
- On 1st October 2020, downgraded by Mizuho to Neutral from Buy rating, with $ 2.50 target price.
Conference Call
Selecta Biosciences, Inc. will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website selectabio.com
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The companys lead product is SEL-212 that in Phase II clinical trials for the treatment of chronic refractory gout.
